Is it safe to abruptly discontinue bupropion (Wellbutrin) while continuing treatment for vertigo?

Abrupt Discontinuation of Bupropion (Wellbutrin) During Vertigo Treatment

Do not abruptly discontinue bupropion (Wellbutrin) regardless of ongoing vertigo treatment, as abrupt cessation can precipitate withdrawal symptoms and, in rare cases, acute dystonia. 1, 2, 3

Key Safety Concerns with Abrupt Bupropion Cessation

Withdrawal Syndrome Risk

• Abrupt discontinuation of bupropion can cause withdrawal symptoms including irritable mood, anxiety, sleeplessness, headache, and generalized aches and pains 2
• Acute dystonia has been documented following abrupt bupropion discontinuation, manifesting as dysphagia, trismus, and torticollis that required either bupropion reinstitution or biperiden injection for resolution 3
• The FDA label explicitly warns that bupropion is contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs due to increased seizure risk 1

Proper Discontinuation Protocol

• Taper bupropion gradually rather than stopping abruptly to minimize withdrawal symptoms and other adverse events 2
• The FDA label does not specify a mandatory taper schedule for bupropion itself, but clinical experience supports gradual dose reduction 1
• Monitor closely for neuropsychiatric symptoms during any dose changes, including agitation, mood changes, anxiety, and suicidal ideation 1

Bupropion and Vertigo Treatment: No Direct Interaction

Vestibular Suppressants Are Not Recommended for BPPV

• Vestibular suppressant medications (antihistamines, benzodiazepines) are not recommended for treatment of benign paroxysmal positional vertigo (BPPV) except for short-term management of severe nausea or vomiting 4, 5
• A 2023 systematic review confirmed that vestibular suppressants may have no effect on symptom resolution in BPPV patients, whereas canalith repositioning maneuvers (CRMs) demonstrate clear superiority 6
• Bupropion is not a vestibular suppressant and does not interfere with vertigo treatment or vestibular rehabilitation 4

Bupropion Does Not Contraindicate Vertigo Management

• There is no evidence that bupropion interferes with canalith repositioning procedures, vestibular rehabilitation training, or other evidence-based BPPV treatments 5, 6
• Continue bupropion during vertigo treatment unless there are independent reasons to discontinue the antidepressant 1

Clinical Algorithm for Managing This Scenario

Step 1: Assess the Indication for Bupropion

• If prescribed for depression, smoking cessation, or other approved indications, maintain therapy unless there is a compelling medical reason to stop 1
• Bupropion has proven efficacy for depression and may be particularly beneficial in patients with comorbid depressive symptoms 7, 8

Step 2: Optimize Vertigo Treatment Independently

• Perform canalith repositioning maneuvers as the primary treatment for BPPV rather than relying on medications 5, 6
• Avoid adding vestibular suppressants unless the patient has severe vegetative symptoms (nausea, vomiting) that are refractory to other measures 4
• Offer vestibular rehabilitation training, which is a protective factor against prolonged residual dizziness 9

Step 3: If Bupropion Discontinuation Is Necessary

• Never stop abruptly—implement a gradual taper over several weeks 2
• Monitor for withdrawal symptoms: irritability, anxiety, insomnia, headache, generalized pain 2
• Watch for rare but serious complications such as acute dystonia (dysphagia, trismus, torticollis) 3
• Reassess within 1 month to confirm symptom resolution and ensure no adverse effects from medication changes 5

Important Caveats

Seizure Risk Considerations

• Bupropion lowers the seizure threshold in a dose-dependent manner, with risk increasing substantially above 450 mg/day 1
• Do not abruptly discontinue bupropion in patients taking benzodiazepines or other CNS depressants, as this creates a dual risk: withdrawal symptoms from bupropion and increased seizure risk from the abrupt change 1
• If the patient is on benzodiazepines for vertigo-related anxiety (which is not recommended), taper the benzodiazepine gradually—25% dose reduction every 1-2 weeks—rather than stopping abruptly 10

Monitoring During Dose Changes

• Monitor blood pressure during bupropion therapy and any dose adjustments, as treatment can cause hypertension 1
• Assess for neuropsychiatric adverse events including agitation, depression, mania, psychosis, and suicidal ideation, particularly in the first weeks of therapy or during dose changes 1
• In patients with renal impairment (GFR <90 mL/min), dose reduction may be necessary 1

Special Populations

• Older adults (≥65 years) may experience falls as a complication of combination antidepressant therapy, though this risk is primarily associated with adding bupropion to existing treatment rather than continuing stable monotherapy 11
• Patients with diabetes mellitus or depression are at higher risk for prolonged residual dizziness after BPPV and may benefit from continued antidepressant therapy 9